Location:
South Pacific F, Lower Level, North Convention Center
PRESENTER:
Click the plus sign to see more detailed information about each speaker.
Annie Wong-Beringer, PharmD, Associate Professor, University of Southern California School of Pharmacy
Dr. Annie Wong-Beringer is an Associate Professor and Vice Chair of the Department of Clinical Pharmacy at the School of Pharmacy, University of Southern California. She received her PharmD degree from the USC School of Pharmacy and completed her post-doctoral Pharmacy Practice Residency and Fellowship training in Infectious Diseases at the University of California, San Francisco. She has authored numerous articles on original research, review articles, and book chapters in the area of antimicrobial resistance. Her research program focuses on the mechanisms and impact of bacterial resistance and virulence on patient outcomes (specifically MRSA and Pseudomonas) and her research program has been funded by the National Institute of Health NIAID. Her expertise in the field has led to her recent appointments completing a 3-year term on the FDA Anti-infective Drugs Advisory Committee and also serving on the IDSA Standards and Guidelines Committee. She has been an Infectious Diseases Specialty Residency program director since 2000 and has recently become the Program Director of Ph.D. in Clinical and Experimental Therapeutics.
PROGRAM CHAIR:
Click the plus sign to see more detailed information about each speaker.
Annie Wong-Beringer, PharmD, Associate Professor, University of Southern California School of Pharmacy
Dr. Annie Wong-Beringer is an Associate Professor and Vice Chair of the Department of Clinical Pharmacy at the School of Pharmacy, University of Southern California. She received her PharmD degree from the USC School of Pharmacy and completed her post-doctoral Pharmacy Practice Residency and Fellowship training in Infectious Diseases at the University of California, San Francisco. She has authored numerous articles on original research, review articles, and book chapters in the area of antimicrobial resistance. Her research program focuses on the mechanisms and impact of bacterial resistance and virulence on patient outcomes (specifically MRSA and Pseudomonas) and her research program has been funded by the National Institute of Health NIAID. Her expertise in the field has led to her recent appointments completing a 3-year term on the FDA Anti-infective Drugs Advisory Committee and also serving on the IDSA Standards and Guidelines Committee. She has been an Infectious Diseases Specialty Residency program director since 2000 and has recently become the Program Director of Ph.D. in Clinical and Experimental Therapeutics.
Develop an alternative treatment plan in the event AKI develops.
Evaluate a monitoring plan to facilitate early detection of AKI.
Identify risk factors that predispose to the development of antibiotic-induced acute kidney injury (AKI).